EW EDWARDS LIFESCIENCES CORP

Edwards Lifesciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

IRVINE, Calif.--(BUSINESS WIRE)--

Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the J.P. Morgan Healthcare Conference on Tuesday, Jan. 14, 2025.

Bernard Zovighian, chief executive officer, is scheduled to present at 11:15 a.m. PT. Scott Ullem, chief financial officer, will also participate in the conference. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at , with an archived version accessible later the same day.

About Edwards Lifesciences

Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeholders, our employees are inspired by our patient-focused culture to deliver life-changing innovations to those who need them most. Discover more at and follow us on LinkedIn, Facebook, Instagram and YouTube.

Edwards, Edwards Lifesciences, and the stylized E logo are trademarks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners.

EN
07/01/2025

Underlying

EWEDWARDS LIFESCIENCES CORP

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on EDWARDS LIFESCIENCES CORP

 PRESS RELEASE
Free
EW EDWARDS LIFESCI...

Edwards Lifesciences to Present at the 43rd Annual J.P. Morgan Healthc...

IRVINE, Calif.--(BUSINESS WIRE)-- Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the J.P. Morgan Healthcare Conference on Tuesday, Jan. 14, 2025. Bernard Zovighian, chief executive officer, is scheduled to present at 11:15 a.m. PT. Scott Ullem, chief financial officer, will also participate in the conference. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at , with an archived version accessible later the same day. About Edwards Lifesciences Edwards Lifesciences is the leading global structur...

January 7, 2025 1 EN
EW EDWARDS LIFESCIENCES CORP
12/12/24 December 12, 2024 1 EN
 PRESS RELEASE
Free
EW EDWARDS LIFESCI...

Edwards Lifesciences Outlines Growth Strategy at Annual Investor Confe...

NEW YORK--(BUSINESS WIRE)-- Edwards Lifesciences Corporation (NYSE: EW) will discuss the company’s focused strategy for long-term sustainable growth, provide an update on its technology pipeline to serve more patients and share financial guidance today during its annual investor conference. Edwards enters 2025, its first full year as a purely structural heart company, in a strong position with major growth drivers in Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral and Tricuspid Therapies (TMTT), the continued long-term performance of Surgical, and future opportunities wi...

December 4, 2024 1 EN
Free Trial
EW EDWARDS LIFESCI...

Edwards Lifesciences Corp: 1 director

A director at Edwards Lifesciences Corp sold 25,000 shares at 65.915USD and the significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...

EW EDWARDS LIFESCIENCES CORP
11/06/24 November 6, 2024 1 EN
 PRESS RELEASE
Free
EW EDWARDS LIFESCI...

Edwards Lifesciences Reports Third Quarter Results

IRVINE, Calif.--(BUSINESS WIRE)-- Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended Sept. 30, 2024. Highlights and Outlook Q3 sales from continuing operations grew 9%; constant currency1 sales grew 10% Q3 TAVR sales grew 6%; constant currency1 sales grew 7% TMTT sales grew 73%; PASCAL and EVOQUE commercial launches continue to progress well Q3 EPS of $5.13; adjusted1 EPS of $0.67 Completed sale of Critical Care in Q3, resulting in significant one-time gain Pivotal TAVR and TMTT clinical evidence to be presented next week at TCT Completed enro...

October 24, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch